Few studies have reported MYCN‐amplification status in neuroblastoma cases diagnosed in individuals with congenital overgrowth syndromes, but the possible connection between this specific subtype and these syndromic conditions requires further study to guide screening and targeted therapy. The gene discussed is MYCN; the disease is neuroblastoma.